Mary Beth Riley - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

Mary Beth Riley

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

Clinical Journal of Oncology Nursing|March 13, 2003

Ibritumomab tiuxetanMary Beth Riley

Seminars in Oncology Nursing|May 27, 2004

The rationale for and background of radioimmunotherapy: an emerging therapy for B-cell non-Hodgkin's lymphomaMary Beth Riley, Katherine Byar

Seminars in Oncology Nursing|May 27, 2004

Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)Mary Beth Riley, Leo I Gordon

American Journal of Clinical Pathology|June 24, 2003

Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic statusJohn L Frater, Martin S Tallman, Daina Variakojis, et al.

Pageof 1

Search research articles

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

Clinical Journal of Oncology Nursing|March 13, 2003

Ibritumomab tiuxetanMary Beth Riley

Seminars in Oncology Nursing|May 27, 2004

The rationale for and background of radioimmunotherapy: an emerging therapy for B-cell non-Hodgkin's lymphomaMary Beth Riley, Katherine Byar

Seminars in Oncology Nursing|May 27, 2004

Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)Mary Beth Riley, Leo I Gordon

American Journal of Clinical Pathology|June 24, 2003

Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic statusJohn L Frater, Martin S Tallman, Daina Variakojis, et al.

Pageof 1